LSEC-Targeted Polymeric Nanoparticles for Antigen-Specific Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for autoimmune and allergic disorders provide only temporary relief and do not offer long-term suppression of chronic disease activity or a cure, highlighting the need for new treatment strategies that induce antigen-specific immune tolerance.
Innovation Solution
Development of biodegradable nanoparticles, such as those made from FDA-approved poly(lactic-co-glycolic acid) (PLGA), designed to target liver sinusoidal endothelial cells (LSECs) using specific surface ligands, enhancing antigen delivery and inducing tolerogenic responses through TGF-β production and antigen-specific Treg generation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional anti-inflammatory, immunosuppressive, or immunomodulatory therapies are used, then symptomatic relief is achieved, but long-term suppression of chronic disease activity or cure is not provided
Solution Approach 1:
The patent applies preliminary action by using biodegradable nanoparticles to pre-deliver antigens to liver antigen-presenting cells before disease flare-ups occur. This proactive antigen delivery primes the immune system to develop long-lasting antigen-specific tolerance, rather than merely suppressing symptoms after they manifest. The nanoparticles are designed to slowly degrade and release antigens over extended periods, creating sustained immunomodulatory effects that address chronic disease activity at its root.
2Reliability
If nanoparticles are used to deliver antigens to antigen-presenting cells, then antigen-specific immune tolerance is induced, but targeted delivery to liver sinusoidal endothelial cells requires complex surface ligand attachment
Solution Approach 1:
The patent uses liver sinusoidal endothelial cells as intermediary targets. These LSECs naturally express scavenger receptors that can be targeted by relatively simple ligand attachments on nanoparticle surfaces. The LSECs then serve as intermediate carriers, taking up the nanoparticles and transferring the antigens to professional antigen-presenting cells like dendritic cells and macrophages. This intermediary approach simplifies the targeting strategy compared to directly targeting multiple APC types with complex multifunctional nanoparticles.
3Productivity
If professional phagocytes are used to eliminate particulate materials, then microscale particles are cleared efficiently, but soluble macromolecules and 200 nm particulates are poorly eliminated
Solution Approach 1:
The patent exploits the specialized local quality of liver sinusoidal endothelial cells, which possess unique clathrin-mediated endocytic pathways optimized for absorbing soluble macromolecules and 200 nm particulates. This is different from the phagocytic pathways of Kupffer cells that handle larger particles. By designing nanoparticles in the 200 nm size range with surface properties matching LSEC scavenger receptors, the patent achieves efficient uptake through this specialized local mechanism, then leverages the liver's natural antigen presentation machinery to induce tolerance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles effectively enhance immune tolerance by increasing TGF-β production and reducing immune responses, characterized by markers like IL-10 and Foxp3, and decreasing IgE and T-helper 2 cytokines, offering a potential long-term solution for autoimmune and allergic disorders.
Implementation Method 1
LSECs are more proficient in eliminating soluble macromolecules and particulates in the 200 nm size range by clathrin-mediated endocytosis
Data Source
AI summary
In various embodiments tolerogenic nanoparticles are provided that induce immune tolerance to one or more desired antigen(s) and/or that reduce an immune response to those antigen(s). In certain embodiments the tolerogenic nanoparticle comprises a nanoparticle comprising a biocompatible polymer; an antigen disposed within or attached to said biocompatible polymer where said antigen comprises an antigen to which immune tolerance is to be induced by administration of said tolerogenic nanoparticle to a mammal; and a first targeting moiety that binds to a scavenger receptor in the liver, and/or a second targeting moiety that binds to a mannose receptor in the liver, and/or a third targeting moiety that binds to hepatocytes, wherein said first and/or second and/or third targeting moiety are attached to the surface of said nanoparticle.